瑞德西韦同情用药治疗重症新型冠状病毒肺炎患者
该报告基于2020年1月25日至3月7日期间接受瑞德西韦同情用药的住院COVID-19患者,纳入标准为确诊SARS-CoV-2感染且呼吸环境空气时氧饱和度≤94%或正在接受氧支持。患者接受10天疗程:第1天静脉给予200 mg,之后9天每日100 mg。61例至少接受一剂的患者中8例数据无法分析,53例纳入分析;基线时30例(57%)接受机械通气,4例(8%)接受体外膜氧合。中位随访18天,36例(68%)氧支持等级改善,包括30例机械通气中17例(57%)拔管;25例(47%)出院,7例(13%)死亡。
要点
- 53例重症COVID-19患者接受瑞德西韦10天疗程(第1天200 mg静脉,之后每日100 mg共9天),36例(68%)氧支持等级改善。
- 30例基线机械通气患者中17例(57%)拔管;4例(8%)基线接受体外膜氧合。
- 中位随访18天,25例(47%)出院,7例(13%)死亡;有创通气者死亡18%(6/34),无创通气者死亡5%(1/19)。
- 该报告为同情用药队列,作者指出疗效评估需要正在进行的随机安慰剂对照试验。
适用人群与场景
- 确诊SARS-CoV-2感染、呼吸环境空气时氧饱和度≤94%或正在接受氧支持的住院COVID-19患者。
- 数据来自2020年1月25日至2020年3月7日期间接受瑞德西韦且至少有1个后续临床数据日的患者。
诊断标准与关键阈值
- 纳入条件:确诊SARS-CoV-2感染,且呼吸环境空气时氧饱和度≤94%或正在接受氧支持。
处置流程与药物剂量
- 瑞德西韦10天疗程:第1天静脉给予200 mg,之后9天每日100 mg。
研究设计与关键结果
- 同情用药队列:61例至少接受一剂瑞德西韦,8例数据无法分析(7例无治疗后数据、1例给药错误),53例纳入分析。
- 53例中22例在美国、22例在欧洲或加拿大、9例在日本;基线30例(57%)接受机械通气,4例(8%)接受体外膜氧合。
- 中位随访18天,36例(68%)氧支持等级改善,包括30例机械通气中17例(57%)拔管;25例(47%)出院,7例(13%)死亡。
- 有创通气者死亡18%(6/34),无创通气者死亡5%(1/19)。
证据类型、等级与局限
- 证据类型:同情用药队列报告。
- 局限:原文未报告局限性。
- 作者结论:疗效评估需要正在进行的瑞德西韦随机安慰剂对照试验。
对床旁实践的改变
- 作者指出,该同情用药队列中观察到的临床改善不能替代疗效评估,瑞德西韦的疗效需通过正在进行的随机安慰剂对照试验测定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.
METHODS: We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.
RESULTS: Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
CONCLUSIONS: In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).
参考来源
- Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020. PMID: 32275812. doi:10.1056/NEJMoa2007016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。